NGS Targeted Amplicon Sequencing for Precision Medicine Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • NGS Targeted Amplicon Sequencing for Precision Medicine's estimated annual revenue is currently $3.1M per year.(i)
  • NGS Targeted Amplicon Sequencing for Precision Medicine's estimated revenue per employee is $155,000

Employee Data

  • NGS Targeted Amplicon Sequencing for Precision Medicine has 20 Employees.(i)
  • NGS Targeted Amplicon Sequencing for Precision Medicine grew their employee count by -5% last year.

NGS Targeted Amplicon Sequencing for Precision Medicine's People

NameTitleEmail/Phone
1
CEO and Co-FounderReveal Email/Phone
2
VP and Sales ManagerReveal Email/Phone
3
Director R&D and OperationsReveal Email/Phone
4
Sr. Director BioinformaticsReveal Email/Phone
5
Market Development Manager, US West Coast and Asia PacificReveal Email/Phone
6
Senior Technical Applications ScientistReveal Email/Phone
7
Business Operations SpecialistReveal Email/Phone
8
Clinical Molecular Pathology Bioinformatics AnalystReveal Email/Phone
9
Quality Management SpecialistReveal Email/Phone
10
Staff Bioinformatics ScientistReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.4M70-8%$53MN/A
#2
$32.4M167-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.8M1813%N/AN/A
#5
$0.8M5-50%N/AN/A
#6
$0.8M100%N/AN/A
#7
$14M90-12%N/AN/A
#8
$0.4M33610%$236.7MN/A
#9
$4.8M62-74%$160MN/A
#10
$3.7M24-8%N/AN/A
Add Company

What Is NGS Targeted Amplicon Sequencing for Precision Medicine?

Headquartered in Hayward, CA, Paragon Genomics is a dynamic and growing company developing and commercializing breakthrough target enrichment solutions for Next-Generation Sequencing (NGS). We are building a team of passionate scientists, engineers and business professionals who thrive in a collaborative entrepreneurial environment. Our patented CleanPlex amplicon sequencing technology solves the urgent throughput and efficiency bottlenecks of targeted sequencing workflow and is applicable to many fast-growing markets in the genomics space. The Company was selected by a distinguished panel into the California Life Science Association F.A.S.T. Program in March 2016 and was accepted into the prestigious Stanford StartX Medicine Accelerator Program in September 2016.

keywords:N/A

N/A

Total Funding

20

Number of Employees

$3.1M

Revenue (est)

-5%

Employee Growth %

N/A

Valuation

N/A

Accelerator

NGS Targeted Amplicon Sequencing for Precision Medicine News

2022-03-30 - Unlocking capacities of genomics for the COVID-19 response ...

However, the use of proprietary next-generation sequencing solutions ... from wastewater using a targeted tiled amplicon-based sequencing...

2022-03-22 - Metagenomics-enabled microbial surveillance

The use of whole-genome sequencing (WGS) for bacteria, ... either done using a targeted amplicon approach that is based on marker genes (for...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2.9M2011%N/A
#2
$3.2M20-37%N/A
#3
$3.1M2033%N/A
#4
$4.1M20-13%N/A
#5
$3.3M215%N/A